NEWSROOM

	Indoco Remedies - Board Meeting adjourned (BSE ANNOUNCEMENT)  September 4, 2008
	Indoco Remedies Board to consider dividend (BSE ANNOUNCEMENT)  August 20, 2008
	Indoco Changes its Financial Year Ending to 31st March  April 24, 2008
	Outcome of Board Meeting - BSE ANNOUNCEMENT  February 25, 2008
	Indoco Remedies Ltd has decided to take up 100% equity stake in Shree Herbal Technologies Ltd (BSE ANNOUNCEMENT)  January 29, 2008
	Indoco Remedies enters into a Joint Venture partnership with US based company to launch Ophthalmics in US  October 18, 2007
	Indoco Remedies geared up for Brazil  July 4, 2007
	Indoco Remedies Ltd. acquires API manufacturing facility  July 4, 2006
	Indoco Remedies Strengthens its Domestic and API Business April 5, 2006
	Indoco Remedies' Goa facility receives, UK- MHRA Nod March 28, 2006
	Indoco Remedies ophthalmic formulations facility at Goa secures US FDA approval February 3, 2006
	Indoco Remedies - Board Meeting adjourned - BSE ANNOUNCEMENT September 4, 2008 Indoco Remedies Ltd has informed BSE that the Board Meeting of the Company convened on September 02, 2008 for consideration of audited financial results and declaration of divided, if any, has been adjourned, and the adjourned meeting will be held on September 05, 2008 for consideration of audited financial results and declaration of dividend, if any, will be considered for the financial year ended March 31, 2008.  ^Top
	Indoco Remedies Board to consider dividend - BSE ANNOUNCEMENT August 20, 2008 Indoco Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on September 02, 2008, inter alia, for considering the audited financial results for the financial year ended on March 31, 2008, and recommendation of dividend, if any, for the financial year 2007- 2008.  ^Top
	Indoco Changes its Financial Year Ending to 31st March April 24, 2008 Indoco Remedies Limited will have March financial year ending from this fiscal. The Board of Directors of Indoco Remedies Limited, which hitherto had a financial year that ended in June, has decided to change its year ending to March with immediate effect. Resultantly, its FY0708 will reflect the performance of a nine-month period ended March 31st, 2008. Mr. Suresh G. Kare, Chairman and Managing Director, Indoco Remedies Limited said, “This corporate action will align our financial year with that commonly followed in the industry facilitating uniform, timely and efficient financial reporting.” The results for the nine (9) month period will be announced by Indoco Remedies Limited on April 30, 2008.  ^Top
	Outcome of Board Meeting - BSE ANNOUNCEMENT February 25, 2008 Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 23, 2008, has approved the following: 1. Change of Company's financial year ending from June 30th to March 31st. Consequently, the financial year of the Company for 2007-08 will be for a 9 months period from July 01, 2007 to March 31, 2008. 2. A Scheme of Amalgamation for a proposal to amalgamate Company's 100% subsidiary, Shree Herbal Technologies Ltd., with the Company. Further the Company has informed that, the Board of Directors of the Company has accepted the resignation of Mr. Atul S Rajadhyaksha as Director w.e.f. February 23, 2008 and has appointed Mr. Sharad P Upasani as the Director w.e.f. February 23, 2008 in the vacancy caused by the resignation of Mr. Atul S Rajadhyaksha.  ^Top
	Indoco Remedies Ltd has decided to take up 100% equity stake in Shree Herbal Technologies Ltd (BSE ANNOUNCEMENT) January 29, 2008 Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 29, 2008, has decided to take up 100% equity stake in Shree Herbal Technologies Ltd (SHTL) for a consideration of Rs 251.00 lacs. The investment will make SHTL a wholly owned subsidiary of the Company. SHTL is an unlisted Company with registered office at Delhi. It was incorporated in 2005 and is yet to commence manufacturing operations. The Company will leverage its manufacturing capacity from the investment.  ^Top
	Indoco Remedies enters into a Joint Venture partnership with US based company to launch Ophthalmics in US October 18, 2007 Mumbai, October 18, 2007: Indoco Remedies Limited and Amneal Pharmaceuticals, a New Jersey-based developer, manufacturer and distributor of generic pharmaceuticals announce the finalization of a joint venture partnership to develop, manufacture, market and distribute several products for the United States market. The initial product pipeline will include at least ten ophthalmic products, several of which have already progressed substantially through the development process. Under the terms of this agreement, the expertise of each company will be leveraged to create a highly efficient and effective product flow, from API manufacturing through regulatory approval and distribution that will bring at least ten high-quality generic drugs to the US market over the next five years. The product selection committee, made up of three members from each company, chose the first group of products to build a balanced offering in the ophthalmic category, providing potential customers a single source for the most important molecules of the category. Indoco’s responsibilities within the joint venture are, API manufacturing for the majority of these products, formulation development, analytical method development, production of bioequivalence batches, data reporting and ultimately manufacturing of the approved generic drugs for export to U.S. Amneal’s role in the partnership is to prepare and file the ANDAs for US FDA approval using the emerging eCTD/QBR/QOS process, maintaining all required FDA and regulatory agency documentation both prior to and following approval as well as to exclusively sell, market and distribute these products throughout the US pharmaceutical market across all segments. With balanced input from both Amneal and Indoco, funding for developing all these products, including bio-study costs, legal fees and other development expenses, will be equally shared. Likewise, the financial benefit from the sale of these products will be shared. For additional development after this initial group of products, Indoco and Amneal have already begun to identify several more products to pursue, in the ophthalmic category as well as other therapeutic categories and dosage forms. The two companies fully expect this agreement to expand significantly in the near term and for it to last for many years. In Amneal, Indoco now has a young and growing US generic company as a partner to market their ophthalmic products in USA. This partnership will help Indoco to speedily introduce their products in the U.S. market and to explore other areas of growth opportunities in the largest generic market of the world.  ^Top
	Indoco Remedies geared up for Brazil July 4, 2007 Indoco Remedies Solid Dosage facility at Goa secures ANVISA, Brazil approval. Mumbai, July 4, 2007: Indoco Remedies Ltd today announced that its solid dosage facility at Goa, Plant I has received approval from Brazilian food and drug agency, ANVISA, marking the beginning of company’s foray into one of the largest pharmaceutical market in the world. This approval paves way for contract manufacturing opportunities for Indoco in Brazil. Ms. Aditi Kare Panandikar, Director Business development said, "As a part of companies growth strategy & to move up the value chain, Indoco Remedies intends to enter newer, semi-regulated and regulated markets worldwide after getting approvals from the respective regulatory authorities”.  In addition, Indoco Remedies is working towards obtaining MCC approvals, for their Solid dosage as well as Sterile Plants. Out of Company’s two manufacturing facilities at Goa, Plant I is approved by MHRA-UK, for Tablets, Cream & Capsules and by Darmstadt Germany for Solid Dosages. Plant II is a state-of-the-art sterile facility for Ophthalmics and Injectables approved by USFDA.  ^Top
	Indoco Remedies Ltd. acquires API manufacturing facility July 4, 2006 Mumbai, July 4, 2006: Indoco Remedies Limited, today announced the acquisition of La NovaChem’s API manufacturing facility, located at Patalganga, Maharashtra. The acquisition has been effected by acquiring the shares of La NovaChem (India) Pvt. Ltd., the company owning the said facility, thereby making La NovaChem a 100% subsidiary of Indoco. The facility is built on U.S. FDA standards and Indoco will apply for an approval shortly.  The acquisition La NovaChem facility, a state-of-the-art unit, is a strategic step by the company to build its in-house API manufacturing capability both for the domestic as well as exports business. Recently, Indoco commissioned it’s newly set-up R&D Centre at Rabale near Thane, which primarily targets API synthesis and development, and is also equipped with a kilo-lab facility. Indoco is increasingly looking to expand its business from other geographies, specially the regulated markets of US and Europe. Indoco’s Goa plant for sterile ophthalmic preparations is US FDA approved. This will facilitate the production and export of the company's ophthalmic preparations to USA. Indoco has signed agreements with two generic companies in USA and will supply products from the Goa facility. The company is looking at filing a total of 7 ANDA’s by December 2006. The market size of the products aggregates USD 1.1 bn.  Commenting on the acquisition, Mr. Suresh Kare, Chairman and Managing Director of Indoco Remedies Ltd said, “The acquisition of La NovaChem’s U.S. FDA approvable API facility, and the recent commissioning of the API focused R&D facility, would fortify and substantially hasten Indoco’s strategy of backward integration and targeting of regulated markets of U.S and Europe. It will also help INDOCO build its strong presence in API markets, both in India and abroad”.  ^Top
	Indoco Remedies Strengthens its Domestic and API Business April 5, 2006 Baddi manufacturing plant commences operations  Inaugurates new R&D Centre to boost its API business April 5, 2006, Mumbai: Indoco Remedies Limited’s state-of-the-art manufacturing facility at Baddi, Himachal Pradesh, has commenced manufacturing operations. The Company has also announced the opening of its new R&D Centre for API’s (Active Pharmaceutical Ingredients) at Rabale, Navi Mumbai. Both these projects, i.e. the manufacturing facility at Baddi and R&D Centre at Navi Mumbai, were part of the declared objectives of the Company for its maiden IPO about a year ago.  The Baddi facility has been set up at a cost of Rs.30 crore. The new facility will support the Company’s growing formulations requirements for the domestic as well as international business. It is owned by the company’s 100% subsidiary - Indoco Healthcare Limited.  The new R&D Centre, set up at a cost of Rs.20 crore, will substantially boost the Company's prospects in the API business. The Company aims to launch its API business and is looking out for acquisition of suitable facilities.  Commenting on the occasion, Mr. Suresh Kare, Chairman & Managing Director of Indoco Remedies said, “we are looking at increasing our revenues from API’s and the starting of the R&D centre will be the beginning of a new growth phase for Indoco. Our manufacturing capabilities will be further enhanced with the addition of the Baddi facility.”  ^Top
	Indoco Remedies' Goa facility receives, UK- MHRA Nod March 28, 2006 Mumbai, March 28, 2006: … Indoco Remedies Ltd., one of India’s fastest growing pharmaceutical companies has successfully completed the MHRA, UK Audit of its Goa facility for tablets, creams, ointments & capsules. The nod extends to the "Pilot Facility" in the new tablet area. With approval of this pilot plant Indoco will be in a position to conduct validation batches for Clinical trials / BE studies for products to be registered in Europe, which in turn will give Indoco a right to supply the products for a period of five years from the date of commercial launch by its customers. Mr. Suresh Kare, Chairman & Managing Director, Indoco Remedies said, “We successfully completed Audit of our new tablet facility as well as its capsules and semisolids line. This demonstrates confidence by the international regulatory bodies in our manufacturing capabilities and strengths. The approval of the Creams as well as Capsules facility will enable Indoco to export two additional dosage forms to UK. Also on account of mutual recognition, the approvals open up the rest of Europe, Australia & New Zealand as territories for export of formulations. This is a right step forward in the direction of achieving our vision of becoming a 1000 crore company by 2010.” Indoco's Goa facility has a team of over 100 employees who are engaged in manufacturing world-class products. The Tablet Manufacturing unit has a capacity to produce 3 billion tablets per annum.  Indoco has a strong domestic presence and has strategically aligned itself for a giant leap to be a global player. The company’s state-of-the-art manufacturing facilities adhere to the highest international standards and this has primarily contributed to Indoco's success in formulations exports to the European Market. ^Top
	Indoco Remedies ophthalmic formulations facility at Goa secures US FDA approval February 3, 2006 Mumbai, February 3, 2006: Indoco Remedies Ltd today announced that it has received US FDA approval for its sterile ophthalmic preparations facility at the Goa plant (plant-II). This will facilitate the production and export of the company's ophthalmic preparations to USA (and other regulated markets or rest of the world). Indoco has signed an agreement with Nexus Ophthalmic of USA and will supply products under the contract from the Goa facility. The company is looking at filing a total of 7 ANDA’s by June 2006 (its financial year ending). Mr. Suresh G. Kare, Chairman & Managing Director, Indoco Remedies Ltd. said “we are increasingly looking to expand our business from other geographies. For the US market we have adopted a partnering model with local companies. In the coming months we will file more ANDA’s and increase our business from this important pharma market. The USFDA approval is a step in our quest to be global players.”  ^Top